Genelux (GNLX) Convertible Debt (2022 - 2023)

Genelux (GNLX) posted Convertible Debt of $40000.0 for Q3 2023, down 38.46% on a QoQ basis from $65000.0 in Q2 2023.

Analysis

Genelux (GNLX) Convertible Debt (2022 - 2023) Analysis & Trends

Genelux has reported Convertible Debt for 2 years, with the latest figure at $40000.0 in Q3 2023.

On a quarterly basis, Convertible Debt changed N/A year-over-year to $40000.0 in Q3 2023; TTM through Sep 2023 was $40000.0, a N/A change from a year earlier, with the FY2022 full-year figure at $15.4 million, changed N/A from the prior year.
Convertible Debt was $40000.0 for Q3 2023 at Genelux, down from $65000.0 in the prior quarter.
The five-year high for Convertible Debt was $15.4 million in Q4 2022, with the low at $40000.0 in Q3 2023.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Amgen	206.44 Bn	192.45 Bn	7.24 Bn
2	Gilead Sciences	179.97 Bn	176.79 Bn	6.22 Bn
3	Vertex Pharmaceuticals	130.57 Bn	122.72 Bn	2.84 Bn
4	Regeneron Pharmaceuticals	81.63 Bn	73.63 Bn	3.93 Bn
5	Argenx Se	60.34 Bn	55.16 Bn	1.37 Bn
6	Moderna	54.37 Bn	49.23 Bn	52.00 Mn
7	Alnylam Pharmaceuticals	33.07 Bn	29.76 Bn	992.69 Mn
8	Biogen	31.84 Bn	30.55 Bn	1.96 Bn
9	Roivant Sciences	29.49 Bn	29.49 Bn	1.16 Mn
10	Genelux	108.17 Mn	108.17 Mn	-

Historic Data

Download Data